Can Tatva sustain Q1's momentum as expansion gains pace?
After a blockbuster Q1 with revenue +43% and PAT +140% YoY, Tatva reports Q2 FY27 on Oct 19. Analysts on Hold at ₹1,443 (vs ₹1,871 now) worry about valuation, not execution—but the Street's own ₹6.39b FY27 forecast implies momentum holds. Watch margin stability and capex timing as the Dahej expansion ramps.
The setup: Q1 was a 40-point revenue sprint. Will Q2 hold the pace?
Tatva Chintan opened FY27 with results that nearly doubled PAT year-on-year and grew consolidated revenue 43% to ₹167.1 Cr. That's a powerful start. The driver was a favorable product mix (specialty chemicals pricing holding), strong order execution, and operating leverage kicking in. The question for Q2 is margin durability as the company pivots into capex mode: Dahej III groundbreaking was July 20; capex outlays will depress reported profits. The Street wants to see EBITDA margin resilience and any forward guidance on FY27 that locks in the growth story.
~₹350–380 Cr
Q1 was ₹167.1 Cr; expect mid-to-high 30s% YoY growth (specialty chem demand intact) and ~20% sequential growth
~22–25%
Q1's margin expansion was stellar. Watch for any compression as capex ramps; management guidance on DPI/capex intensity critical
Check split
Q1 showed consolidated growth outpacing standalone. Verify if subsidiary (overseas/specialty) is driving or if mix has shifted
Watch leverage ratio
Dahej III capex will inflate debt in H1 FY27. Management's DPI/leverage ceiling key to longer-term confidence
What a strong print looks like: Revenue ₹360+ Cr with YoY growth >35%, EBITDA margin ≥23%, and management reaffirming or raising FY27 guidance (implying sustained momentum through H2). A beat on PAT would signal capex isn't yet biting into profits. What a weak print looks like: Revenue coming in below ₹340 Cr or YoY growth slipping below 25%, margin compression >100bp QoQ, and management guiding flat or lower for Q3–Q4 (suggests demand normalization or pricing pressure). Any commentary on Dahej delays or revised capex timeline would also spook the market.
On track for FY27?
Analysts collectively forecast ₹6.39b (₹639 Cr) for FY27, a 15% rise on the trailing twelve months. Q1 alone was ₹167.1 Cr, so the full-year math implies Q2–Q4 average of ~₹157 Cr each—a slight step-down from Q1's exceptional run but still robust growth vs. prior-year quarters. For that to hold, Q2 needs to print ₹350+ Cr. Anything south of ₹330 Cr would signal the boom may be peaking. Current Street consensus on EPS (₹30.50, +39% FY27 vs. FY26) is aggressive; it depends on margin staying >22% and tax rate stable around 25%. Management's tone on full-year guidance will be the real tell: if they raise or anchor FY27, confidence holds; if they hedge, watch multiples compress.
What the Street says
Since Q1: what's changed
The big operational news is the Dahej III greenfield expansion—a ₹400–500 Cr capex bet on specialty chemical capacity that management approved July 17 and broke ground July 20. This is a multi-year ramp; Q2 will reflect early site prep spend and financing costs, but volume uplift won't materialize until Q4 FY27 or later. In August, the company announced the resignation of Ajay Rawat, Assistant VP (R&D)—a senior management exit that warrants a management question: does it signal pipeline delays, cost-cutting, or routine rotation? The promoter stake remains rock-solid at 72.02% (unchanged since FY25 Q1), and FII/DII flows are modest and stable. No red flags on pledges or insider selling. The board approved a final dividend of ₹2.00 per share for FY26 (20% payout), consistent with historical practice.
1 · Margin trajectory and capex intensity
Does EBITDA margin hold ≥23%, or does Dahej capex + debt servicing eat into Q2? Management must clarify expected capex for the full year and any debt-to-EBITDA covenant comfort. A margin compression >150bp would suggest execution risk.
2 · Full-year guidance and volume outlook
Will management reaffirm ₹6.39b FY27 revenue guidance, or raise/lower? Any comment on demand conditions, export orders, or pricing power for specialty chemicals? Dahej ramp timeline is key—when do new lines come online, and what capex remains?
3 · R&D head exit—pipeline implications
The August resignation of the R&D head needs context. Is this a routine move, or does it signal delays in new product launches that were fueling growth? Management's commentary on product pipeline maturity and near-term launch cadence will determine if this is a blip or a concern.
Tatva Chintan has set a high bar with Q1 FY27's 43% revenue and 140% PAT growth, and the Street's ₹6.39b full-year forecast implies momentum holds—but thin analyst coverage and a 23% valuation discount to the current stock price suggest the market sees execution risk or macro headwinds ahead. Q2 will be a test of whether the specialty chemicals boom is sustainable as the company pivots into the Dahej expansion capex cycle. Investors should focus on EBITDA margin resilience, full-year guidance confidence, and any color on the R&D transition. A solid print with margin-positive commentary could re-rate the stock upward; any stumble would validate the Street's caution.
Result date: October 19, 2026.